Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.88 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.88 |
| ▸ | PDE8A | O60658 | 3/20 | 0.88 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100771 | 1.00 | PDE7A (0.88) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL30837836 | 0.94 | PDE7A (0.88) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL99882 | 0.94 | PDE7A (0.88) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL30837881 | 0.94 | PDE7A (1.00) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100704 | 0.94 | PDE7A (1.00) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL99921 | 0.92 | PDE7A (0.88) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100878 | 0.92 | PDE7A (0.93) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL100865 | 0.92 | PDE7A (0.87) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL30837796 | 0.92 | PDE7A (0.93) | PDE7APDE7BPDE8AOPRM1OPRL1 | |
| SCHEMBL30837943 | 0.92 | PDE7A (0.93) | PDE7APDE7BPDE8AOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |